KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Return on Equity (2016 - 2025)

Arbutus Biopharma's Return on Equity history spans 12 years, with the latest figure at 0.53% for Q3 2025.

  • For Q3 2025, Return on Equity rose 14.0% year-over-year to 0.53%; the TTM value through Sep 2025 reached 0.53%, up 14.0%, while the annual FY2024 figure was 0.69%, 9.0% down from the prior year.
  • Return on Equity for Q3 2025 was 0.53% at Arbutus Biopharma, up from 0.67% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.44% in Q2 2022 and bottomed at 0.87% in Q1 2025.
  • The 5-year median for Return on Equity is 0.61% (2021), against an average of 0.59%.
  • The largest annual shift saw Return on Equity soared 154bps in 2021 before it fell -19bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.51% in 2021, then grew by 3bps to 0.49% in 2022, then plummeted by -31bps to 0.65% in 2023, then decreased by -6bps to 0.68% in 2024, then grew by 23bps to 0.53% in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Return on Equity are 0.53% (Q3 2025), 0.67% (Q2 2025), and 0.87% (Q1 2025).